Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MPI | P34949 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 3/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30129411 | 1.00 | ERN1 (0.46) | ERN1TDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8544546 | 0.80 | CYP1A2 (0.39) | ERN1TDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29952839 | 0.80 | CYP1A2 (0.39) | ERN1TDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16168598 | 0.78 | ERN1 (0.43) | ERN1TDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2119952 | 0.78 | ERN1 (0.39) | ERN1TDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2237321 | 0.78 | ERN1 (0.46) | ERN1TDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL2214871 | 0.78 | ERN1 (0.39) | ERN1TDP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2600016 | 0.78 | ERN1 (0.43) | ERN1TDP1PLAUORAI1HPGD | |
| SCHEMBL127596 | 0.78 | ERN1 (0.43) | ERN1TDP1CYP1A2PLAUORAI1 | |
| SCHEMBL1619507 | 0.78 | ERN1 (0.54) | ERN1TDP1PLAUORAI1PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113214182-B | Benzisothiazole compound and preparation method thereof | 佛山湘潭大学绿色智造研究院 | 2022-12-23 | — | — | CN | claimed |
| CN-113214182-A | Benzisothiazole compound and preparation method thereof | 佛山湘潭大学绿色智造研究院 | 2021-08-06 | — | — | CN | claimed |
| CN-112662639-A | Short-chain alcohol dehydrogenase and application thereof | 江南大学 | 2021-04-16 | — | — | CN | claimed |
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-12 | — | — | US | disclosed |
| EP-4169925-B1 | PROCESS TO MAKE N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-06-17 | — | — | US | disclosed |
| US-20240352030-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-10-24 | — | — | US | disclosed |
| US-20240327411-A1 | SIRT6 ACTIVATORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-10-03 | — | — | US | disclosed |
| US-12012417-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-06-18 | — | — | US | disclosed |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4055013-B1 | WDR5 INHIBITORS AND MODULATORS | UNIV VANDERBILT (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-1583533-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1438298-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | Pfizer Products Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040092529-A1 | Methods of using piperazine derivatives | PFIZER INC | 2004-05-13 | — | — | US | disclosed |
| WO-2004039376-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040034034-A1 | Novel piperazine derivatives | BLUMBERG LAURA C (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2003035627-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | PFIZER PRODUCTS INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-0702003-B1 | Process for preparing 2-halogenpyridinaldehydes | BAYER AG (DE) | 1998-06-17 | — | — | EP | disclosed |
| US-5708180-A | CYCLIZATION OF UNSATURATED NITRILE, AMIDE OR OXIME | BAYER AKTIENGESELLSCHAFT (DE) | 1998-01-13 | — | — | US | disclosed |
| EP-0702003-A2 | Process for preparing 2-halogenpyridinaldehydes and new 2-halogenpyridinaldehydes | BAYER AG (DE) | 1996-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092529-A1 | Methods of using piperazine derivatives | CCR1, CCR3, CCR5 | ERN1 3658/4885TDP1 2298/4885CYP1A2 571/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | ERN1 2560/4885TDP1 4511/4885CYP1A2 2774/4885 |
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | TPMT, NNMT, NLN | ERN1 2167/4885TDP1 992/4885CYP1A2 2516/4885 |
| US-20240327411-A1 | SIRT6 ACTIVATORS | SIRT6, SIRT1, SIRT2 | ERN1 1981/4885TDP1 2644/4885CYP1A2 3910/4885 |
| US-20040034034-A1 | Novel piperazine derivatives | CCR1, CCRL2, CCR5 | ERN1 3417/4885TDP1 2705/4885CYP1A2 720/4885 |
| US-20240352030-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | TPMT, SARS1, NLN | ERN1 1613/4885TDP1 729/4885CYP1A2 2339/4885 |
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | CCR3, SCN1B, NR3C1 | ERN1 883/4885TDP1 2046/4885CYP1A2 1279/4885 |
| US-12012417-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | TPMT, NNMT, NLN | ERN1 2073/4885TDP1 799/4885CYP1A2 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.